J&J Wins U.S. FDA Approval for Long-Acting Version of Pain Pill

Johnson & Johnson (JNJ) won U.S. clearance to sell an extended-release version of the Nucynta pain drug.

The Food and Drug Administration approved the twice-daily pill, also known as tapentadol, to treat chronic pain in adults, the company said today in a statement. The therapy, an opiate, has crush-resistant properties to deter abuse.

The shorter-acting version of New Brunswick, New Jersey- based J&J’s drug gained FDA approval in November 2008 for acute pain. The Drug Enforcement Administration classifies Nucynta as a schedule II controlled substance, meaning distribution is restricted because of a high potential for abuse. Sales of Nucynta may reach $262 million next year, according to the average estimate of two analysts surveyed by Bloomberg.

J&J, the world’s second-biggest maker of health products, said in October that the extended-release version had failed to win approval because the FDA wanted more information about the drug’s tamper-resistant formulation. The company submitted the additional data in February.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.